Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 32, Issue 6, Pages 497-511Publisher
WILEY
DOI: 10.1002/dmrr.2775
Keywords
GLP-1 receptor agonist; intensification; exenatide; lixisenatide; algorithms; latent autoimmune diabetes in adults (LADA)
Categories
Funding
- Sanofi
Ask authors/readers for more resources
A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. (C) 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available